Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) announces that it has granted 250,000 incentive stock options (the “Options”) at an exercise price of $0.85 per common share for a five year term.
Further, the Company has granted 50,000 restricted share rights (the “RSRs”) with a one-eight (1/8th) of the RSRs to vest every three months beginning April 21, 2021.
The Options and RSRs were granted to a director of the Company under the Company’s Equity Incentive Plan.
The Company also announces that it has issued an aggregate of 384,896 common shares (the “Common Shares”) at a deemed price of $0.96 per Common Share in the capital of the Company to certain consultants of the Company for past services rendered to the Company.
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.